Homology Medicines, Inc. (FIXX): Price and Financial Metrics

Homology Medicines, Inc. (FIXX): $0.93

0.01 (+0.77%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

D

FIXX Price/Volume Stats

Current price $0.93 52-week high $1.48
Prev. close $0.93 52-week low $0.46
Day low $0.90 Volume 401,400
Day high $0.97 Avg. volume 390,307
50-day MA $0.78 Dividend yield N/A
200-day MA $0.91 Market Cap 54.34M

FIXX Stock Price Chart Interactive Chart >

FIXX POWR Grades

  • FIXX scores best on the Growth dimension, with a Growth rank ahead of 69.22% of US stocks.
  • FIXX's strongest trending metric is Stability; it's been moving down over the last 26 weeks.
  • FIXX ranks lowest in Momentum; there it ranks in the 18th percentile.

FIXX Stock Summary

  • With a price/sales ratio of 17.43, HOMOLOGY MEDICINES INC has a higher such ratio than 93.7% of stocks in our set.
  • Over the past twelve months, FIXX has reported earnings growth of 3,674.46%, putting it ahead of 99.75% of US stocks in our set.
  • Revenue growth over the past 12 months for HOMOLOGY MEDICINES INC comes in at -38.96%, a number that bests merely 6.7% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to FIXX, based on their financial statements, market capitalization, and price volatility, are MRNS, ERIC, CEVA, MRUS, and PSTX.
  • FIXX's SEC filings can be seen here. And to visit HOMOLOGY MEDICINES INC's official web site, go to www.homologymedicines.com.

FIXX Valuation Summary

  • In comparison to the median Healthcare stock, FIXX's price/sales ratio is 328.57% higher, now standing at 18.
  • FIXX's price/sales ratio has moved NA NA over the prior 70 months.

Below are key valuation metrics over time for FIXX.

Stock Date P/S P/B P/E EV/EBIT
FIXX 2023-12-29 18.0 0.4 -0.3 -0.3
FIXX 2023-12-28 17.0 0.4 -0.3 -0.2
FIXX 2023-12-27 16.7 0.4 -0.2 -0.2
FIXX 2023-12-26 16.9 0.4 -0.3 -0.2
FIXX 2023-12-22 16.9 0.4 -0.3 -0.2
FIXX 2023-12-21 16.9 0.4 -0.3 -0.2

FIXX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • FIXX has a Quality Grade of D, ranking ahead of 17.28% of graded US stocks.
  • FIXX's asset turnover comes in at 0.134 -- ranking 233rd of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows FIXX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.134 1 -1.031
2021-03-31 0.128 1 -1.267
2020-12-31 0.010 1 -1.629
2020-09-30 0.008 1 -0.944
2020-06-30 0.007 1 -0.719
2020-03-31 0.006 1 -0.566

FIXX Price Target

For more insight on analysts targets of FIXX, see our FIXX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $23.20 Average Broker Recommendation 1.32 (Strong Buy)

Homology Medicines, Inc. (FIXX) Company Bio


Homology Medicines, Inc., a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders. The company’s various set of AAVHSCs allows company to target, via a single intravenous injection, a range of disease-relevant tissues, including the liver, central nervous system, bone marrow, lung, muscle and eye, across modalities—gene editing and gene therapy. The company was founded in 2015 and is based in Bedford, Massachusetts.


FIXX Latest News Stream


Event/Time News Detail
Loading, please wait...

FIXX Latest Social Stream


Loading social stream, please wait...

View Full FIXX Social Stream

Latest FIXX News From Around the Web

Below are the latest news stories about HOMOLOGY MEDICINES INC that investors may wish to consider to help them evaluate FIXX as an investment opportunity.

Homology enters reverse merger with Q32 Bio

The deal, which will result in a combined company operating under Q32's name, comes months after Homology laid off much of its staff.

Yahoo | November 16, 2023

Q32 Bio and Homology Medicines Announce Merger Agreement

--The combined company will operate as Q32 Bio Inc., advancing the development of Q32 Bio’s two clinical development candidates, bempikibart (ADX-914) in Phase 2 for the treatment of atopic dermatitis (AD) and alopecia areata (AA), and ADX-097 entering Phase 2 for the treatment of complement disorders-- --Q32 Bio has re-acquired worldwide development and commercial rights to bempikibart, an anti-IL-7Rα antibody inhibiting IL-7 and TSLP-mediated signaling, and remains on-track to report multiple

Yahoo | November 16, 2023

Homology Medicines Reports Third Quarter 2023 Financial Results

- Continuing to Evaluate Strategic Options for the Company and the Pipeline of Genetic Medicines, including HMI-103 - BEDFORD, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today third quarter 2023 financial results and highlighted recent updates. Homology recently shared a summary of safety and efficacy data on the first dose cohort of the pheEDIT clinical trial evaluating the Company’s HMI-103 gene editing candidate for

Yahoo | November 14, 2023

Can Homology Medicines (NASDAQ:FIXX) Afford To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Yahoo | October 28, 2023

Homology Medicines Reports Second Quarter 2023 Financial Results and Recent Highlights

- Reported Encouraging Initial Data from First Cohort of Phase 1 Trial Evaluating Gene Editing Candidate HMI-103 in Adults with PKU - - Evaluating Strategic Options for the Company and Pipeline of Genetic Medicines, including HMI-103 - BEDFORD, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today second quarter 2023 financial results and highlighted recent updates. “We recently shared the encouraging initial data from the

Yahoo | August 14, 2023

Read More 'FIXX' Stories Here

FIXX Price Returns

1-mo -94.35%
3-mo -91.50%
6-mo -95.58%
1-year -94.88%
3-year -99.44%
5-year -99.81%
YTD -91.50%
2023 -51.75%
2022 -65.38%
2021 -67.76%
2020 -45.46%
2019 -7.42%

Continue Researching FIXX

Want to see what other sources are saying about Homology Medicines Inc's financials and stock price? Try the links below:

Homology Medicines Inc (FIXX) Stock Price | Nasdaq
Homology Medicines Inc (FIXX) Stock Quote, History and News - Yahoo Finance
Homology Medicines Inc (FIXX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!